The third-quarter 2024 reporting cycle of the Medical sector is about to end as most firms have already reported their earnings results. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off around mid-October when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently raised its total revenue expectation for the year while lowering its adjusted earnings e ...